View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAyala Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Ayala Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 09OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).OS Therapies Incorporated (NYSEAM:OSTX) agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $8 million on January 29, 2025. A cash consideration of $0.5 million will be paid by OS Therapies Incorporated. Under the terms of the agreement, OS Therapies has agreed to pay $0.5 million in cash and issue $7.5 million worth of OS Therapies’ common shares to Ayala. OS Therapies previously completed a $7.1 million financing, priced at $4.00 per share primarily with existing shareholders, that provides the Company with sufficient cash runway into 2026 inclusive of payments to Ayala. As part of the financing agreement, OS Therapies agreed to appoint Karim Galzahr to the Company’s Board of Directors. The transaction is expected to close 60 days from execution of the agreement, subject to customary closing conditions. OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on April 9, 2025.お知らせ • May 10Ayala Pharmaceuticals Files Form 15Ayala Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Apr 04+ 1 more updateAndres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, IncOn March 25, 2024, upon the previously announced consummation of the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Purchase Agreement”), dated as of February 5, 2024, between Ayala Pharmaceuticals, Inc. and Immunome, Inc. (“Purchaser”), Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.お知らせ • Apr 02Ayala Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ayala Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 27Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).Immunome, Inc. (NasdaqCM:IMNM) entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $94.2 million on February 6, 2024. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval. A.G.P./Alliance Global Partners is acting as strategic advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction. Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on March 26, 2024.お知らせ • Feb 20Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid TumorsAyala Pharmaceuticals, Inc. announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. The Phase 3 segment of the RINGSIDE study is a double-blind, multi-center trial enrolling patients with progressive disease, randomized between AL102 1.2 mg dosed once daily or placebo. The primary endpoint is progression-free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR), and patient-reported Quality of Life (QOL) measures. RINGSIDE has been designed as a registration study to support a New Drug Application (NDA) in desmoid tumors.お知らせ • Oct 25Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023Ayala Pharmaceuticals, Inc. announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK. The ongoing Phase 2/3 RINGSIDE clinical trial is a randomized, global multi-center study evaluating AL102 in patients with progressing desmoid tumors. The study consists of two parts: Phase 2 (Part A) is an open-label, dose regimen finding study, and Phase 3 (Part B) is a double blind, placebo-controlled study and Open Label Extension utilizing the 1.2 mg once daily dose regimen selected based on data from Phase 2. Patients in Phase 2 were randomized to one of three dose regimens of AL102 (n=14 each), including 1.2 mg once daily (QD), 4 mg twice a week (BIW) or 2 mg BIW. Patients in the intermittent dosing arms were allowed to rollover to the Open Label Extension to receive 1.2 mg once daily after evaluations were completed in the Phase 2 part. The results presented at ESMO reflect a cut-off date as of July 5, 2023. Efficacy Results: 1.2 mg once daily achieved ORR of 83% per RECIST in the evaluable population as assessed by MRI BICR (Blinded Independent Central Review). ORR per RECIST was 64% in evaluable patients across the 3 dose arms (n=36). Efficacy results continue to demonstrate a dose-response pattern favoring the 1.2 mg once daily arm. First Partial Responses (PRs) observed at 16 weeks and 21 additional PRs and 1 Complete Response across all dose arms. Early and deep volume (-52%) and T2 signal intensity (-58%) reductions within 16 weeks after starting 1.2 mg once daily. Best overall median reductions of 88% and 85% in volume and T2 signal intensity, respectively, in the 1.2 mg once daily arm at 16.6 months of median time on treatment. Reductions in volume and T2 signal intensity were also observed across biweekly dose arms. 29 patients rolled over to the OLE between Oct 2022 and May 2023, with 27 still on study. Three patients from the 4 mg BIW arm achieved PR after rolling over to the OLE where they received 1.2 mg once daily. Safety: AL102 was generally well tolerated with a manageable safety profile across all dose arms. Adverse events (AEs) were consistent with gamma secretase inhibitors’ (GSI) mec anism of action. The most frequent treatment-related AEs with 1.2 mg once daily included diarrhea (92.8%), nausea (57.1%), fatigue (50%), dry skin (50%), alopecia (50%), stomatitis (50%) dermatitis acneiform (42.9%), dry mouth (42.9%), hypophosphatemia (42.9%), rash maculopapular (37.7%) and aspartate aminotransferase increased (28.6%). Regardless of dose regimen, AEs were Grade 1 or Grade 2 in >95% of the cases. There was one Grade 4 unrelated AE and no Grade 5 AEs. There were no treatment-related serious AEs. Ovarian dysfunction was reported in 56% of pre-menopausal women in the 1.2 mg once daily arm and 61% of pre-menopausal women across all dose arms.お知らせ • Oct 23Ayala Pharmaceuticals, Inc. Announces CFO ChangesEffective as of the Effective Time, Roy Golan, CPA, LLM, will become the Ayala Pharmaceuticals, Inc.'s Chief Financial Officer. Igor Gitelman will cease to serve as the company's Interim Chief Financial Officer at that time. Mr. Golan, 50, is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of $1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University. Mr. Golan will continue, until such time as new compensation terms are agreed to with the Company, to be compensated in accordance with his existing arrangements at Biosight, including an annual salary of approximately $180,000, and insurance, severance, pension, disability and study fund benefits typical under Israeli employment arrangements. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ayala Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ADXS - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20230-48-29-29N/A12/31/20221-38-35-35N/Aアナリストによる今後の成長予測収入対貯蓄率: ADXSの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ADXSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ADXSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ADXSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ADXSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ADXSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/05 12:41終値2026/02/03 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ayala Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ahu DemirLadenburg Thalmann & Company
お知らせ • Apr 09OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).OS Therapies Incorporated (NYSEAM:OSTX) agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $8 million on January 29, 2025. A cash consideration of $0.5 million will be paid by OS Therapies Incorporated. Under the terms of the agreement, OS Therapies has agreed to pay $0.5 million in cash and issue $7.5 million worth of OS Therapies’ common shares to Ayala. OS Therapies previously completed a $7.1 million financing, priced at $4.00 per share primarily with existing shareholders, that provides the Company with sufficient cash runway into 2026 inclusive of payments to Ayala. As part of the financing agreement, OS Therapies agreed to appoint Karim Galzahr to the Company’s Board of Directors. The transaction is expected to close 60 days from execution of the agreement, subject to customary closing conditions. OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on April 9, 2025.
お知らせ • May 10Ayala Pharmaceuticals Files Form 15Ayala Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Apr 04+ 1 more updateAndres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, IncOn March 25, 2024, upon the previously announced consummation of the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Purchase Agreement”), dated as of February 5, 2024, between Ayala Pharmaceuticals, Inc. and Immunome, Inc. (“Purchaser”), Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.
お知らせ • Apr 02Ayala Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ayala Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 27Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).Immunome, Inc. (NasdaqCM:IMNM) entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $94.2 million on February 6, 2024. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval. A.G.P./Alliance Global Partners is acting as strategic advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction. Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on March 26, 2024.
お知らせ • Feb 20Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid TumorsAyala Pharmaceuticals, Inc. announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. The Phase 3 segment of the RINGSIDE study is a double-blind, multi-center trial enrolling patients with progressive disease, randomized between AL102 1.2 mg dosed once daily or placebo. The primary endpoint is progression-free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR), and patient-reported Quality of Life (QOL) measures. RINGSIDE has been designed as a registration study to support a New Drug Application (NDA) in desmoid tumors.
お知らせ • Oct 25Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023Ayala Pharmaceuticals, Inc. announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK. The ongoing Phase 2/3 RINGSIDE clinical trial is a randomized, global multi-center study evaluating AL102 in patients with progressing desmoid tumors. The study consists of two parts: Phase 2 (Part A) is an open-label, dose regimen finding study, and Phase 3 (Part B) is a double blind, placebo-controlled study and Open Label Extension utilizing the 1.2 mg once daily dose regimen selected based on data from Phase 2. Patients in Phase 2 were randomized to one of three dose regimens of AL102 (n=14 each), including 1.2 mg once daily (QD), 4 mg twice a week (BIW) or 2 mg BIW. Patients in the intermittent dosing arms were allowed to rollover to the Open Label Extension to receive 1.2 mg once daily after evaluations were completed in the Phase 2 part. The results presented at ESMO reflect a cut-off date as of July 5, 2023. Efficacy Results: 1.2 mg once daily achieved ORR of 83% per RECIST in the evaluable population as assessed by MRI BICR (Blinded Independent Central Review). ORR per RECIST was 64% in evaluable patients across the 3 dose arms (n=36). Efficacy results continue to demonstrate a dose-response pattern favoring the 1.2 mg once daily arm. First Partial Responses (PRs) observed at 16 weeks and 21 additional PRs and 1 Complete Response across all dose arms. Early and deep volume (-52%) and T2 signal intensity (-58%) reductions within 16 weeks after starting 1.2 mg once daily. Best overall median reductions of 88% and 85% in volume and T2 signal intensity, respectively, in the 1.2 mg once daily arm at 16.6 months of median time on treatment. Reductions in volume and T2 signal intensity were also observed across biweekly dose arms. 29 patients rolled over to the OLE between Oct 2022 and May 2023, with 27 still on study. Three patients from the 4 mg BIW arm achieved PR after rolling over to the OLE where they received 1.2 mg once daily. Safety: AL102 was generally well tolerated with a manageable safety profile across all dose arms. Adverse events (AEs) were consistent with gamma secretase inhibitors’ (GSI) mec anism of action. The most frequent treatment-related AEs with 1.2 mg once daily included diarrhea (92.8%), nausea (57.1%), fatigue (50%), dry skin (50%), alopecia (50%), stomatitis (50%) dermatitis acneiform (42.9%), dry mouth (42.9%), hypophosphatemia (42.9%), rash maculopapular (37.7%) and aspartate aminotransferase increased (28.6%). Regardless of dose regimen, AEs were Grade 1 or Grade 2 in >95% of the cases. There was one Grade 4 unrelated AE and no Grade 5 AEs. There were no treatment-related serious AEs. Ovarian dysfunction was reported in 56% of pre-menopausal women in the 1.2 mg once daily arm and 61% of pre-menopausal women across all dose arms.
お知らせ • Oct 23Ayala Pharmaceuticals, Inc. Announces CFO ChangesEffective as of the Effective Time, Roy Golan, CPA, LLM, will become the Ayala Pharmaceuticals, Inc.'s Chief Financial Officer. Igor Gitelman will cease to serve as the company's Interim Chief Financial Officer at that time. Mr. Golan, 50, is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of $1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University. Mr. Golan will continue, until such time as new compensation terms are agreed to with the Company, to be compensated in accordance with his existing arrangements at Biosight, including an annual salary of approximately $180,000, and insurance, severance, pension, disability and study fund benefits typical under Israeli employment arrangements.